In the meantime, Stephens downgraded its Elevation Oncology Inc [ELEV] rating to an Equal-weight from a an Overweight in a research note published on March 24, 2025; the price target was decreased to $1 from $5. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who decreased its forecast for the stock in late March from “an Overweight” to “a Neutral”. Leerink Partners also remained covering ELEV and has decreased its forecast on March 21, 2025 with a “Market perform” recommendation from previously “an Outperform” rating. Citizens JMP revised its rating on March 21, 2025. It rated ELEV as “a Mkt perform” which previously was an “a Mkt outperform”.
Price Performance Review of ELEV
On Tuesday, Elevation Oncology Inc [NASDAQ:ELEV] saw its stock jump 1.23% to $0.34. Over the last five days, the stock has lost -2.28%. Elevation Oncology Inc shares have fallen nearly -39.83% since the year began. Nevertheless, the stocks have fallen -91.14% over the past one year. While a 52-week high of $4.33 was reached on 01/13/25, a 52-week low of $0.22 was recorded on 04/09/25. SMA at 50 days reached $0.3750, while 200 days put it at $0.6923.
Levels Of Support And Resistance For ELEV Stock
The 24-hour chart illustrates a support level at 0.3305, which if violated will result in even more drops to 0.3225. On the upside, there is a resistance level at 0.3460. A further resistance level may holdings at 0.3535. The Relative Strength Index (RSI) on the 14-day chart is 47.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0184, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.46%. Stochastics %K at 48.18% indicates the stock is a holding.
The most recent change occurred on January 03, 2025 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating .
